Publikationsserver der Universitätsbibliothek Marburg

Titel:Die Plasma-Sensibilität auf Heparin und Enoxaparin
Autor:Ajib, Salem Abdulfatah
Weitere Beteiligte: Stief, T. (Prof. Dr.)
Veröffentlicht:2013
URI:https://archiv.ub.uni-marburg.de/diss/z2014/0033
DOI: https://doi.org/10.17192/z2014.0033
URN: urn:nbn:de:hebis:04-z2014-00335
DDC: Medizin
Titel (trans.):The Plasma Sensibility to Heparin and Enoxaparin
Publikationsdatum:2014-01-14
Lizenz:https://rightsstatements.org/vocab/InC-NC/1.0/

Dokument

Schlagwörter:
Heparin, Enoxaparin, Enoxaparin, Sensibilität, Sensibility, Heparin, Plasma, Plasma

Zusammenfassung:
Unfraktioniertes Heparin (UFH) und niedermolekulares Heparin (NMH) sind die am häufigsten verwendeten klinischen Antikoagulantien zur Therapie von Patienten mit venösen Thromboembolien (VTE), akutem Koronarsyndrom (ACS) und für Thromboseprophylaxe in Krankenhäusern. Die klinische Tendenz favorisiert zunehmend NMH, auch intravenös, z.B. beim transmuralen Myokardinfarkt (STEMI). Der extrinsische Gerinnungs-Aktivitätstest (EXCA) wurde im Hauptteil der Arbeit bei 51 normalen Citratplasmen oder 213 Citratplasmen der Patienten (bei normaler PT und APTT in Abwesenheit von NMH) nach 50 μl Supplementierung mit 0-1 IU/ml UFH oder NMH durchgeführt. Der recalcifizierte Gerinnungsaktivitätstest (RECA) wurde im Nebenteil der Arbeit mit 10 normalen Citratplasmen und in 32 Citratplasmen der Patienten nach 50 μl Supplementierung mit 0-10 mIU/ml UFH oder NMH durchgeführt. 1 IU/ml Enoxaparin reduzierte die normale Thrombin-Generierung in EXCA auf etwa 13% der Norm, während bei 1 IU/ml Heparin die normale Thrombin-Generierung komplett supprimiert wurde. Dies bedeutet, dass 1 IU/ml Enoxaparin ein stark therapeutisches Antikoagulans ist, während 1 IU/ml UFH bereits im toxischen Bereich ist. 0.01 IU/ml Heparin oder Enoxaparin reduzierte die normale Thrombin-Generierung in EXCA nur um etwa 10% oder 20%. UFH bei 0.1 mIU/ml reduzierte die Thrombin-Generierung im RECA nicht, sondern erhöhte sogar die Thrombin-Generierung um etwa 20%, während 0.1 mIU/ml NMH signifikant die Thrombingenerierung um etwa 30% -60% hemmte. Dies bedeutet, dass Heparin in ultra-niedrigen Konzentrationen, wie z. B. am Ende der Heparin-Infusion, besonders für Patienten mit sensibler intrinsischer Hämostase gefährlich werden könnte. Es wird vorgeschlagen, mit NMH das Ende der Heparin-Infusion zu überbrücken oder UFH auf NMH umzustellen. Diese Ergebnisse unterstützen das Konzept, dass die Dosierung der NMHs für jeden Patienten individuell durch einen ultra-spezifischen Thrombin-Generierungstest (EXCA oder INCA (intrinsischer Gerinnungs-Aktivitätstest)) angepasst werden sollte. Die Dosierung der NMH soll individuell entsprechend dem Ziel der Antikoagulation (prophylaktisch oder therapeutisch) und dem plasmatischen Ansprechen auf das Heparin angepaßt werden. Zielaktivität für therapeutische oder prophylaktische Antikoagulation sind 10-20% oder 20-40% der normalen Trigger-induzierten Thrombin-Generierung respektiv. Die adäquate Dosierung des NMH beim individuellen Patienten sollte durch einen spezifischen Thrombin-Generierungstest kontrolliert werden.

Bibliographie / References

  1. Rosand J, Eckman MH, Knudsen KA, Singer DE, Greenberg SM. (2004). "The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. "Arch Intern Med 164: 880-4.
  2. Stief TW, Wieczerzak A, Renz H. (2008). "The Extrinsic Coagulation Activity Assay. "Clin Appl Thromb Hemost 14: 303-18.
  3. Nicolaes GA, Dahlback B. (2002). "Factor V and thrombotic disease: description of a janus-faced protein." Arterioscler Thromb Vasc Biol 22: 530-538.
  4. Munoz EM, Linhardt RJ. (2004). "Heparin-binding domains in vascular biology." Arterioscler Thromb Vasc Biol 24: 1549-1557.
  5. Van Dongen CJ, van den Belt AG, Prins MH, Lensing AW. (2004). "Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism." Cochrane Database Syst Rev 18: CD001100.
  6. "Molecular profiling and weight determination of heparins and depolymerized heparins." J Pharm Sci 84: 724-727.
  7. Carney. (2009). "Thrombin and Thrombin Peptides in Wound Healing and Tissue Repair." thrombin pp 115-132.
  8. Weibo Luo, Yingfei Wang, and Georg Reiser. (2009). "The Role of Thrombin and Thrombin Receptors in the Brain." thrombin pp 133-159.
  9. Kornalik, F. & Blomback, B. (1975). "Prothrombin activation induced by Ecarin -a prothrombin converting enzyme from Echis carinatus venom." Thromb Res 6: 57-63.
  10. Menajovsky LB. (2005). "Heparin-induced thrombocytopenia: clinical manifestations and management strategies." Am J Med 118 (suppl 8A): 21S-30S.
  11. Schousboe I. (2008). "Pharmacological regulation of factor XII activation may be a new target to control pathological coagulation." Biochem Pharmacol 75: 1007-1013.
  12. Krem MM, Cera ED. (2002). "Evolution of enzyme cascades from embryonic development to blood coagulation." Trends Biochem Sci 27: 67-74.
  13. O'Brien DP, Johnson D, Byfield P, Tuddenham EGD. (1992). "Inactivation of factor VIII by factor IXa." Biochemistry 31: 2805-2812.
  14. Bahou, W.F. (2002). "Attacked from within, blood thins." Nature Medicine 8(10): 1082-3.
  15. Salom RN, Maguire JA, Hancock WW. (1998). "Endothelial activation and cytokine expression in human acute cardiac allograft rejection." Pathology 30: 24-29.
  16. Soslau, G., Goldenberg, S.J., Class, R. & Jameson, B. (2004). "Differential activation and inhibition of human platelet thrombin receptors by structurally distinct a-,b-and g- thrombin." Platelets 15: 155.
  17. Pervin A, Gallo C, Jandik KA, Han XJ, Linhardt RJ. (1995). "Preparation and structural characterization of large heparin-derived oligosaccharides." Glycobiology 5: 83-95.
  18. Mosessom MW, Kaminiski W. (1990). "The acceleratory effect of thrombin on fibrin clot assembly." Blood Coagul Fibrinolysis 1: 475-478.
  19. Stief TW. (2007). "The anticoagulant capacity of plasmatic unfractionated heparin decreases at 23°C." Blood Coagul Fibrinolysis 18: 209-12.
  20. Stief TW. Contact activation of coagulation depends on the maximal lipophilic trigger concentration. " Blood Coagulation and Fibrinolysis 2012, 23: 296-298.
  21. Stief TW. (2008). "Influence of the surface on thrombin generation." Int J Lab Hemat 30: 269-77.
  22. Sonnenblick M, et al. (1975). "Hyper-transaminasemia with heparin therapy." BMJ 3: 77
  23. Hirsh J, Levine MN. (1992). "Low molecular weight heparin." Blood 79: 1-17.
  24. Odén A, Fahlén M. (2002). "Oral anticoagulation and risk of death: a medical record linkage study." BMJ 325: 1073-5.
  25. Hirsh J. (1991). "Heparin." N Engl J Med 324: 1565-1574.
  26. Watts GF, et al. (1991). "Lipoprotein lipase deficiency due to long-term heparinization presenting as severe hypertriglyceridaemia in pregnancy." Postgrad Med J 67: 1062-4.
  27. Toyoda K, Okada Y, Ibayashi S, Inoue T, Yasumori K, Fukui D, Uwatoko T, Makihara N, Minematsu K. (2007). " Antithrombotic therapy and predilection for cerebellar hemorrhage. Cerebrovasc Dis 23: 109-16.
  28. Sinauridze EI, Kireev DA, Popenko NY, Pichugin AV, Panteleev MA, Krymskaya OV, Ataullakhanov FI. (2007). "Platelet microparticle membranes have 50-to 100-fold higher specific procoagulant activity than activated platelets." Thromb Haemost 97: 425-34.
  29. Stief TW. (2006). "Specific Determination of Plasmatic Thrombin Activity." Clin Appl Thromb Hemost 12: 324-329.
  30. Stief TW. (2007). "Arginine Inhibits Serpins." Clinical and Applied Thrombosis/Hemostasis 13: 213-218.
  31. Stief TW. (2008). "Innovative tests of plasmatic hemostasis." Laboratory Medicine 39: 225-30.
  32. Nutescu EA, Shapiro NL, Chevalier A, Amin AN. (2005;2006). "A pharmacologic overview of current and emerging anticoagulants." Cleve Clin J Med 72 (Suppl 1): S2- S6.
  33. Hirsh J, Weitz J. (1999). "New antithrombotic agents." Lancet 353: 1431-1436.
  34. Bara L , Samama M . (1988). "Pharmacokinetics of low molecular weight heparins." Acta Chir Scand Suppl 543: 65-72 .
  35. Mulloy B, Gee C, Wheeler SF, Wait R, Gray E, Barrowcliffe TW. (1997). "Molecular weight measurements of low molecular weight heparins by gel permeation chromatography." Thromb Haemost 77: 668-674.
  36. Wisloff F, Jacobsen EM, Liestol S. (2003). "Laboratory diagnosis of the antiphospholipid syndrome." Thromb Res 108: 26371.
  37. Jewett B (ed). (1892). "The Dialogues of Plato, 3rd ed." New York, Macmillan pp 339- 543.
  38. Tillett WS, Garner RL. (1933). "The fibrinolytic activity of hemolytic streptococci." J Exp Med 58: 485-502.
  39. Hirsh J, Raschke R. (2004). " Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy." Chest 126: 188S– 203S.
  40. Stief TW. (2007). "The efficiency of anti-activated factor X and anti-activated factor II anticoagulants." Blood Coagul Fibrinolysis 18: 265-9.
  41. Monreal M, et al. (1989). "Adverse effects of three different forms of heparin therapy: thrombocytopenia, increased transaminases, and hyperkalaemia." Eur J Clin Pharmacol 37: 415–18.
  42. Owren PA. Thrombotest. (1959). "A new method for controlling anticoagulant therapy." Lancet 2: 754-8.
  43. Thackrah CT. (1819). "An Inquiry into the Nature and Properties of the Blood. " London, Cox & Sons.
  44. Visentin GP, Ford SE, Scott JP, et al. (1994). "Antibodies from patients with heparin- induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells." J Clin Invest 93: 81–88.
  45. Andersson LO, Barrowcliffe TW, Holmer E, et al. (1976). "Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin III and by gel filtration." Thromb Res 9: 575-583.
  46. Triplett DA. (2002). "Antiphospholipid antibodies." Arch Pathol Lab Med 126: 1424-9.
  47. Stief TW, Weippert M, Kretschmer V, Renz H. (2001). "Arginine Inhibits Hemostasis Activation." Thromb Res 104: 265–274.
  48. Nesheim, M.E., Eid, S. & Mann, K.G. (1981). "Assembly of the prothrombinase complex in the absence of prothrombin." J Biol Chem 256: 9874-9882.
  49. Quick AJ, Stanley-Brown M, Bancroft FW. (1935). "A study of the coagulation defect in hemophilia and in jaundice. " Am J Med Sci 190: 501-11.
  50. Silverberg M, Dunn JT, Garen L, et al. (1980). "Autoactivation of human Hageman factor. Demonstration utilizing a synthetic substrate." J Biol Chem 255: 7281-7286.
  51. Kalafatis M, Lu D, Bertina RM, Long GL, Mann KG. (1995). "Biochemical prototype for familial thrombosis. A study combining a functional protein C mutation and factor V Leiden." Arterioscler Thromb Vasc Biol 15: 2181-2187.
  52. Kelton JG, Hirsh J. (1980). "Bleeding associated with antithrombotic therapy." Semin Hematol 17: 259–291.
  53. Hemker H. Coenraad, Peter Giesena, Raed Al Dieria, Véronique Regnaultb, Suzette Béguina. (2003). "Calibrated Automated Thrombin Generation Measurement in Clotting Plasma." Pathophysiol Haemost Thromb 33: 4-15.
  54. Mills CA. (1921). "Chemical nature of tissue coagulants." J Biol Chem 46: 135-165.
  55. Scott CF, Silver LD, Purdon AD, et al. (1985). "Cleavage of human high molecular weight kininogen by factor XIa in vitro. Effect on structure and function." J Biol Chem 260: 10856-10863.
  56. Wu, S.M., Cheung, W.F., Frazier, D. & Stafford, D.W. (1991). "Cloning and expression of the cDNA for human gamma-glutamyl carboxylase." Science 254: 1634- 1636.
  57. Jenny NS, Mann KG. (1998). "Coagulation cascade: an overview. In: Loscalzo J, Schafer AI (eds) Thrombosis and hemorrhage." Williams and Wilkins, Baltimore pp 3- 27.
  58. Van Cott EM, Laposata M. Coagulation, fibrinolysis, and hypercoagulation. In: Henry JB, editor. (2001). "Clinical diagnosis and management by laboratory methods, twentieth edition. " Philadelphia:W.B. Saunders Co 642– 59.
  59. Olson JD, Arkin CF, Brandt JT, et al. (1998). "College of American Pathologists Conference XXXI on Laboratory Monitoring of Anticoagulant Therapy: laboratory monitoring of unfractionated heparin therapy." Arch Pathol Lab Med 122: 782–98.
  60. Vogel GM, Meuleman DG, Bourgondien FG, et al. (1989). "Comparison of two experimental thrombosis models in rats effects of four glycosaminoglycans." Thromb Res 54: 399-410.
  61. Schmaier AH. (1997). "Contact activation: a revision." Thromb Haemost 78: 101
  62. Atha DH, Lormeau JC, Petitou M, Rosenberg RD, Choay J. (1985). "Contribution of monosaccharide residues in heparin binding to antithrombin III." Biochemistry 24: 6723-6729.
  63. O'Donnell BF, Tan CY. (1993). "Delayed hypersensitivity reactions to heparin." Br J Dermatol 129: 634–6.
  64. Petit JL. (1731). "Dissertation sur la manniere d'arrester le sang dans les hemorrhagies. " Mem Acad R Sci 1: 85-102.
  65. Montvale, NJ. (2006). "Enoxaparin (low-molecular weight heparin). Physicians' Desk Reference, sixtieth edition." Thompson PDR 2931-7.
  66. Young E, Wells P, Holloway S, et al. (1994). "Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin." Thromb Haemost 71: 300–304.
  67. Sidi A, Seligsohn U, Jonas P. (1978). "Factor XI deficiency: detection and management during urological surgery." J Urol 119: 528-530.
  68. Rojkjaer R, Hasan AA, Motta G, et al. (1998). "Factor XII does not initiate prekallikrein activation on endothelial cells. " Thromb Haemost 80: 74-81.
  69. Weaver WD, Cerqueira M, Hallstrom AP, et al. (1993). "for the Myocardial Infarction Triage and Intervention Project Group. Prehospital-initiated versus hospital-initiated thrombolytic therapy. Myocardial triage and intervention trial." JAMA 270: 1211- References The Plasma Sensibility to Heparin and Enoxaparin ______________________________________________________________________ 103
  70. Johnson EA, Kirkwood TBL, Stirling Y, et al. (1976). "Four heparin preparations: anti-
  71. Van den Besselaar AM, Poller L, Tripodi A. (1999). "Guidelines for thromboplastins and plasmas used to control oral anticoagulant therapy." WHO Technical Report Series 889: 64.
  72. Riemersma RA, et al. (1981). "Heparin-induced lipolysis, an exaggerated risk." Lancet ii: 471.
  73. Ulrick PJ, Manoharan A. (1984). "Heparin-induced skin reaction." Med J Aust 140: 287-9.
  74. Kandrotas RJ. (1992). "Heparin pharmacokinetics and pharmacodynamics." Clin Pharmacokinet 22: 359-74.
  75. Rajgopal R, Butcher M, Weitz JI , Shaughnessy SG . (2006). "Heparin synergistically enhances interleukin-11 signaling through up-regulation of the MAPK pathway. " J Biol Chem 281: 20780 – 20787.
  76. Sakariassen KS, Bolhuis PA, Sixma JJ. (1979). "Human blood platelet adhesion to artery subendothelium is mediated by factor VIII-von Willebrand factor bound to the subendothelium." Nature 279: 636-638.
  77. Marmur JD, Thiruvikraman SV, Fyfe BS, et al. (1996). "Identification of active tissue factor in human coronary atheroma." Circulation 94: 1226-1232.
  78. Sealey JE, Atlas SA, Laragh JH. (1978). "Linking the kallikrein and renin systems via activation of inactive renin: new data and a hypothesis." Am J Med 65: 994-1000.
  79. Weitz JI. (1997). "Low-molecular-weight heparins." N Engl J Med 337:688-698.
  80. Spaet TH, Zucker MB. (1964). "Mechanism of platelet plug formation and role of adenosine diphosphate." Am J Physiol 206: 1267-1274.
  81. Morrissey JH, Fakhrai H, Edgington TS. (1987). "Molecular cloning of the cDNA for tissue factor, the cellular receptor for the initiation of the coagulation protease cascade. "Cell 50: 129-135.
  82. Harenberg J. (1990). "Pharmacology of low molecular weight heparins." Semin Thromb Hemost 16 ( suppl ): 12-18.
  83. Schmaier AH. (1998). "Plasma contact activation: a revised hypothesis." Biol Res 31: 251-262.
  84. Wuepper KD, Cochrane CG. (1972). "Plasma prekallikrein: isolation, characterization, and mechanism of activation." J Exp Med 135: 1-20.
  85. Marcus AJ. (1969). "Platelet function." N Engl J Med 280: 1213-1220, 1278-1284, 1330-1335.
  86. Sarode R, Rawal A, Lee R, Shen YM, Frenkel EP. (2006). "Poor correlation of supratherapeutic international normalised ratio and vitamin K-dependent procoagulant factor levels during warfarin therapy." Br J Haematol 132: 604-7.
  87. Paborsky LR, Harris RJ. (1990). "Post-translational modifications of recombinant human tissue factor." Thromb Res 60: 367-376.
  88. Harenberg J, Siegele M, Dempde CE, et al. (1993). "Protamine neutralization of the release of tissue factor pathway inhibitor activity by heparins." Thromb Hllemost 70: 942-945.
  89. Schapira M, Scott CF, Colman RW. (1981). "Protection of human plasma kallikrein from inactivation by C1 inhibitor and other protease inhibitors. The role of high molecular weight kininogen." Biochemistry 20: 2738-2743.
  90. Schwalbe RA, Ryan J, Stern DM, et al. (1989). "Protein structural requirements and properties of membrane binding by gamma-carboxyglutamic acid-containing plasma proteins and peptides." J Biol Chem 264: 20288-20296.
  91. Speijer, H., Govers-Riemslag, J.W., Zwaal, R.F. & Rosing, J. (1986). "Prothrombin activation by an activator from the venom of Oxyuranus scutellatus (Taipan snake)." J Biol Chem 261: 13258-13267.
  92. Wachtfogel YT, Pixley RA, Kucich U, et al. (1986). "Purified plasma factor XIIa aggregates human neutrophils and causes degranulation." Blood 67: 1731-1737.
  93. Tracy PB, Eide LL, Bowie EJ, et al. (1982). "Radioimmunoassay of factor V in human plasma and platelets." Blood 60: 59-63.
  94. References The Plasma Sensibility to Heparin and Enoxaparin ______________________________________________________________________ References The Plasma Sensibility to Heparin and Enoxaparin ______________________________________________________________________ References The Plasma Sensibility to Heparin and Enoxaparin ______________________________________________________________________ References The Plasma Sensibility to Heparin and Enoxaparin ______________________________________________________________________ 88
  95. Arieru RA, Faioni EM, Mannucci PM. (1994). "Repeated release of the tissue factor pathway inhibitnr." Thromb Haemost 72(2): 327-328.
  96. Nogami K, Shima M, Hosokawa K, et al. (1999). " Role of factor VIII C2 domain in factor VIII binding to factor Xa." J Biol Chem 274: 31000-31007.
  97. Joseph DR, Baker ME. (1992). "Sex hormone–binding globulin, androgen-binding protein, and vitamin K-dependent protein S are homologous to laminin A, merosin, and Drosophila crumbs protein." FASEB J 6: 2477-2481.
  98. Weiss HJ, Sussman II, Hoyer LW. (1977). "Stabilization of factor VIII in plasma by the von Willebrand factor; studies on post-transfusion and dissociated factor VIII and in patients with von Willebrand's disease." J Clin Invest 60: 390-404.
  99. Tans G, Rosing J, Griffin JH. (1983). "Sulfatide-dependent autoactivation of human blood coagulation Factor XII (Hageman Factor)." J Biol Chem 258: 8215-8222.
  100. Warkentin TE, Kelton JG. (2001). "Temporal aspects of heparin-induced thrombocytopenia." N Engl J Med 344: 1286-92.
  101. Sherry, S. & Troll, W. (1954). "The action of thrombin on synthetic Substrates." J Biol Chem 208: 95-105.
  102. Revak SD, Cochrane CG, Griffin JH. (1977). "The binding and cleavage characteristics of human Hageman factor during contact activation. A comparison of normal plasma with plasmas deficient in factor XI, prekallikrein, or high molecular weight kininogen.
  103. Hemker H C. (2002). "The Calibrated Automated Thrombogram (CAT): a universal routine test for hyperand hypocoagulability." Pathophysiol Haemost Thromb 32: 249- 253.
  104. Nesheim, M.E., Taswell, J.B. & Mann, K.G. (1979). "The contribution of bovine Factor V and Factor Va to the activity of prothrombinase." J Biol Chem 254: 10952- 10962.
  105. Hirsh J, Poller L. (1994). "The international normalized ratio A guide to understanding and correcting its problems." Arch Intern Med 154: 282.
  106. Stief TW. (2012). "The maximal plasma concentration of (delta-) negatively charged contact triggers influences plasmatic thrombin generation. In: Stief T, editor.
  107. Morita, T., Iwanaga, S. & Suzuki, T. (1976). "The mechanism of activation of bovine prothrombin by an activator isolated from Echis carinatus venon and characterization of the new active intermediates." J Biochem 79: 1089-1108.
  108. Nelsestuen, G.L., Zytkovicz, T.H. & Howard, J.B. (1974). "The mode of action of vitamin K. Identification of gamma-carboxyglutamic acid as a component of prothrombin." J Biol Chem 249: 6347-6350.
  109. Neth P, Arnhold M, Nitschko H, et al. (2001). "The mRNAs ofprekallikrein, factors XI and XII, and kininogen, components of the contact phase cascade are differentially expressed in multiple non-hepatic human tissues." Thromb Haemost 85: 1043-1047.
  110. The Plasma Sensibility to Heparin and Enoxaparin ______________________________________________________________________ 80
  111. Quick AJ. (1935). "The prothrombin time in haemophilia and in obstructive jaundice.
  112. Oldenburg J, Marinova M, Muller-Reible C, et al. (2008). "The vitamin K cycle." Vitam Horm 78: 35 62.
  113. Thrombin: function and pathophysiology." New York: Nova Science Publishers pp. 37- 46.
  114. Wolberg, A.S. (2007). "Thrombin generation and fibrin clot structure." Blood Rev 21: 131-142.
  115. Nemerson Y, Repke D. (1985). "Tissue factor accelerates the activation of coagulation factor VII: the role of a bifunctional coagulation cofactor." Thromb Res 40: 351-358.
  116. Warkentin T, et al. (2008). "Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition)." Chest 133 (suppl): 340S–380S.
  117. Weitz JI, Young E, Johnston M, et al. (1999). "Vasoflux, a new anticoagulant with a novel mechanism of action." Circulation 99: 682-689.
  118. Verzeichnis The Plasma Sensibility to Heparin and Enoxaparin ______________________________________________________________________ 107
  119. Nelsestuen GL, Shah AM, Harvey SB. (2000). "Vitamin K-dependent proteins. " Vitam Horm 58: 355-389.
  120. (2004). "Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis." Chest 126: 1938-45.
  121. Nelson-Piercy C. (1998). "Heparin induced osteoporosis." Scand J Rheumatol 27 (suppl 107): 68–71.
  122. Olsson SB, Halperin JL. (2005). "Prevention of stroke in patients with atrial fibrillation." Semin Vasc Med 5: 285-92.
  123. Bates SM, Greer IA, Pabinger I, Sofaer S, Hirsh J. (2008). "Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians evidence based clinical practice guidelines (8th edition) " Chest 133 (suppl): 844S-886S.
  124. Shaughnessy SG, Young E, Deschamps P, et al. (1995). "The effects of low molecular weight and standard heparin on calcium loss from the fetal rat calvaria." Blood 86: 1368–1373.
  125. Tollefsen DM, Majerus DW, Blank MK. (1982). "Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma." J Biol Chem 257: 2162–2169.
  126. Krishnaswamy, S., Church, W.R., Nesheim, M.E. & Mann, K.G. (1987). "Activation of human prothrombin by human prothrombinase Influence of factor Va on the reaction mechanism." J.Biol.Chem 262: 3291.
  127. Andersson LO, Brown JE. (1981). "Interaction of factor VIII-von Willebrand factor with phospholipid vesicles." Biochem J 206: 161-167.
  128. Hedin SG. (1904). "On the presence of a proteolytic enzyme in the normal serum of the ox." J Physiol (Lond) 30: 195-201.
  129. McConnell DJ, Mason B. (1970). "The isolation of human plasma prekallikrein." Br J Pharmacol 38: 490-502.
  130. Williams JRB. (1951). "The fibrinolytic activity of urine." Br J Exp Pathol 32: 530- 537.
  131. Revak SD, Cochrane CG, Bouma BN, et al. (1978). "Surface and fluid phase activities of two forms of activated Hageman factor produced during contact activation of plasma." J Exp Med 147: 719-729.
  132. Wiggins RC, Cochrane CC. (1979). "The autoactivation of rabbit Hageman factor." J Exp Med 150: 1122-1133.
  133. Schmaier AH. (2008). "Assembly, activation, and physiologic influence of the plasma kallikrein/kinin system." Int Immunopharmacol 8: 161-165.
  134. Scott CF, Colman RW. (1980). "Function and immunochemistry of prekallikrein-high molecular weight kininogen complex in plasma." J Clin Invest 65:413-421.
  135. Stenflo J, Fernlund P, Egan W & Roepstorff, P. (1974). "Vitamin K dependent modifications of glutamic acid residues in prothrombin." Proc Natl Acad Sci USA 71: 2730-2733.
  136. Revak SD, Cochrane CG. (1976). "The relationship of structure and function in human Hageman factor: the association of enzymatic and binding activities with separate regions of the molecule." J Clin Invest 57: 852-860.
  137. Toossi Z, Sedor JR, Mettler MA, et al. (1992). "Induction of expression of monocyte interleukin 1 by Hageman factor (factor XII)." Proc Natl Acad Sci USA 89: 11969- 11972.
  138. Hay J. (1813). "Account of a remarkable haemorrhagic disposition, existing in many individuals of the same family." N Engl J Med 2: 221-225.
  139. Willis AL, Vane FM, Kuhn DC, et al. (1974). "An endoperoxide aggregator (LASS) formed in platelets in response to thrombotic stimuli." Prostaglandins 8: 453-507.
  140. Yung LL, Lim F, Khan MMH, et al. (1996). "Neutrophil adhesion on surfaces preadsorbed with high molecular weight kininogen under well-defined flow conditions. " Immunopharmacology 32: 19-23.
  141. Warkentin TE , Kelton JG . (1996). "A 14-year study of heparin induced thrombocytopenia." Am J Med 101: 502-507.
  142. Oster JR, et al. (1995). "Heparin-induced aldosterone suppression and hyperkalemia. "Am J Med 98: 575–86.
  143. Stief TW. (2006). "Inhibition of intrinsic thrombin generation." Drug Targets Insights 2: 6-11.
  144. Mann KG, Hockin MF, Begin KJ, et al. (1997). "Activated protein C cleavage of factor Va leads to dissociation of the A2 domain." J Biol Chem 272: 20678-20683.


* Das Dokument ist im Internet frei zugänglich - Hinweise zu den Nutzungsrechten